IMMX · Insider Trading
Immix Biopharma, Inc. Common Stock
Every open-market purchase and sale reported by IMMX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-29 | Gabriel S Morris | CFO, President | A | +500,000 deriv. | — |
| 2026-05-29 | Ilya M Rachman | CEO and Chairman | A | +500,000 deriv. | — |
| 2026-05-29 | Nancy T Chang | Director | A | +6,250 | — |
| 2026-05-29 | Carey Ng | Director | A | +6,250 | — |
| 2026-05-29 | Magda Marquet | Director | A | +6,250 | — |
| 2026-05-29 | Helen C. Adams | Director | A | +6,250 | — |
| 2026-05-29 | Jane Buchan | Director | A | +6,250 | — |
| 2026-05-29 | Jason Hsu | Director | A | +6,250 | — |
| 2026-05-29 | Yekaterina Chudnovsky | Director | A | +6,250 | — |
| 2025-12-11 | Nancy T Chang | Director | A | — | — |
| 2025-12-10 | Gabriel S Morris | CFO | MIXED | +156,770 | +$129.87K |
| 2025-12-10 | Ilya M Rachman | CEO and Chairman | Buy | +746 | +$4.98K |
| 2025-09-17 | Ilya M Rachman | CEO and Chairman | Buy | +2,500 | +$5.05K |
| 2025-09-17 | Gabriel S Morris | CFO | Buy | +2,600 | +$5.12K |
| 2025-06-23 | Gabriel S Morris | CFO | A | — | — |
| 2025-06-23 | Carey Ng | Director | A | — | — |
| 2025-06-23 | Ilya M Rachman | CEO and Chairman | A | — | — |
| 2025-06-23 | Yekaterina Chudnovsky | Director | A | — | — |
| 2025-06-23 | Jason Hsu | Director | A | — | — |
| 2025-06-23 | Magda Marquet | Director | A | — | — |
| 2025-06-23 | Jane Buchan | Director | A | — | — |
| 2025-06-23 | Helen C. Adams | Director | A | — | — |
| 2025-06-20 | Gabriel S Morris | CFO | Buy | +2,225 | +$5.07K |
| 2025-06-20 | Ilya M Rachman | CEO and Chairman | Buy | +2,178 | +$5.00K |
| 2024-12-26 | Jason Hsu | Director | Buy | +47,700 | +$104.36K |
| 2024-08-26 | Jason Hsu | Director | Buy | +23,100 | +$51.62K |
| 2024-08-19 | Carey Ng | Director | Buy | +10,000 | +$18.60K |
| 2024-07-31 | Jason Hsu | Director | Buy | +9,200 | +$19.52K |
| 2024-06-21 | Jane Buchan | Director | A | — | — |
| 2024-06-21 | Ilya M Rachman | CEO and Chairman | A | — | — |
| 2024-06-21 | Gabriel S Morris | CFO | A | — | — |
| 2024-06-21 | Yekaterina Chudnovsky | Director | A | — | — |
| 2024-06-21 | Carey Ng | Director | A | — | — |
| 2024-06-21 | Helen C. Adams | Director | A | — | — |
| 2024-06-21 | Jason Hsu | Director | A | — | — |
| 2024-06-21 | Magda Marquet | Director | A | — | — |
| 2024-06-10 | Ilya M Rachman | CEO and Chairman | Buy | +2,600 | +$5.54K |
| 2024-06-10 | Gabriel S Morris | CFO | Buy | +2,500 | +$5.30K |
| 2024-06-05 | Gabriel S Morris | CFO | Buy | +3,300 | +$5.97K |
| 2024-06-05 | Ilya M Rachman | CEO and Chairman | Buy | +3,300 | +$5.97K |
| 2024-05-20 | Carey Ng | Director | A | — | — |
| 2024-05-20 | Ilya M Rachman | CEO and Chairman | A | +218,359 | — |
| 2024-05-20 | Jane Buchan | Director | A | +2,459 | — |
| 2024-05-20 | Helen C. Adams | Director | A | +161,981 | — |
| 2024-05-20 | Jason Hsu | Director | A | — | — |
| 2024-05-20 | Gabriel S Morris | CFO | A | +242,500 | — |
| 2024-05-20 | Magda Marquet | Director | A | +46,157 | — |
| 2024-05-14 | Gabriel S Morris | CFO | Buy | +4,500 | +$10.04K |
| 2024-05-14 | Ilya M Rachman | CEO and Chairman | Buy | +4,300 | +$9.66K |
| 2023-12-12 | Jason Hsu | Director | Buy | +56,000 | +$266.92K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Yekaterina Chudnovsky | Director | 3,247,326 | $26.17M |
| Ilya M Rachman | CEO and Chairman | 1,141,683 | $9.20M |
| Carey Ng | Director | 1,051,471 | $8.47M |
| Jason Hsu | Director | 949,250 | $7.65M |
| Nancy T Chang | Director | 925,130 | $7.46M |
| Gabriel S Morris | CFO, President | 718,273 | $5.79M |
| Helen C. Adams | Director | 181,004 | $1.46M |
| Magda Marquet | Director | 72,342 | $583.08K |
| Jane Buchan | Director | 28,705 | $231.36K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IMMX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.